The agreement contemplates that DelSite’s patented GelSite polysaccharide polymer may facilitate the administration and enhance the activity of Homspera, ImmuneRegen’s experimental candidate which has previously demonstrated effectiveness as an anti-influenza agent and vaccine adjuvant when administered intranasally.
The company believes that the GelSite polymer could facilitate self-administration of Homspera by virtue of its physical characteristics and its ability to enable time-delayed release of the active drug. The GelSite polymer has been shown to be well tolerated in animal studies and is classified as ‘generally regarded as safe’, when administered either topically or orally.